**Purpose:** Vascularized composite allograft (VCA) transplantation is a novel transplantation. The interplay between Treg and CD4+ effector, CD8+ T cells is important for allograft acceptance. In this study, we explored and compared the benefits of pre- and post-Tx IL-2C administrations.

**Methods:** We performed the VCA model utilizing Balb/c mice as donor and C57bl/10 mice as recipient. Mice were divided randomly to 6 groups (n=15/group). Group A: control; Group B: post-Tx. IL-2C (inj. POD 0, 1, 2); Group C: Rapamycin (2mg/kg, 28days); Group D: Rapamycin plus post-Tx. IL-2C; Group E: pre-Tx. IL-2C (POD -5, -4, -3); Group F: Rapamycin plus pre-Tx. IL-2C. Signs of allograft rejection were monitored daily. General and local inflammation were assessed using flow-cytometry, qPCR and histopathology analysis.

**Results:** Both pre- and post-Tx. IL-2C administrations prolong VCA survival (p\<0.001) by expanding the Treg number-5 folds than control (p\<0.001), but pre-Tx. IL-2C administration significantly increased survival compared to post-Tx (p\<0.01), due to (1) lower IFN-γ+ CD4+ effector and CD8+ T cells. (2) lower Ki67+ CD4+ effector and CD8+ T cells. (3) increased ratio of Treg to CD8+ T cells. The histopathology analysis supports these results.

**Conclusion:** This is the first detailed research of pre-Tx IL-2C administration. We believe that preconditioning IL-2C strategy can be used clinically and contribute to transplantation tolerance further.
